That is exactly what they are there for
Clinical trials (e.g., SCALE) show that highdose liraglutide can produce significant weight loss and improvements in prediabetes, lipids, and blood pressure when combined with a reducedcalorie diet and increased activity
Instead of focusing solely on the scale, aim for small, manageable goals
Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate)
Additionally, insurance coverage for new drugs typically lags by 612 months after approval
Secondly, GLP-1 receptor agonists carry important safety considerations including risk of pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (based on rodent studies, though human relevance remains uncertain)